Cytoprotective and supportive care agents:

Indications for XERMELO:

In combination with somatostatin analog (SSA) therapy, to treat carcinoid syndrome diarrhea in adults inadequately controlled by SSA therapy.


Take with food. 250mg 3 times daily.


Not established.


Monitor for constipation and/or severe, persistent, or worsening abdominal pain; discontinue if develops. ESRD requiring dialysis: not studied. Pregnancy. Nursing mothers: monitor infant for constipation.

Pharmacologic Class:

Tryptophan hydroxylase inhibitor.


May antagonize CYP3A4 substrates (eg, midazolam); monitor and consider increasing dose of concomitant substrates if necessary. Antagonized by short-acting octreotide; if concomitant use is necessary, give dose ≥30mins after Xermelo.

Adverse Reactions:

Nausea, headache, increased GGT, depression, flatulence, decreased appetite, peripheral edema, pyrexia.

Generic Availability:


How Supplied:

Monthly carton—4 x 7 daily dose packs

Pricing for XERMELO

3 tablets of 250mg dose pack (Qty: 28)
Appx. price $6995